• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Allergan

Allergan

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. Actavis and Allergan Shareholders Approve Proposals Related to Actavis' Planned Acquisition of Allergan

    Actavis and Allergan Shareholders Approve Proposals Related to Actavis' Planned Acquisition of Allergan

  2. American Airlines Group to replace Allergan in the S&P 500

    American Airlines Group to replace Allergan in the S&P 500

  3. UPDATE: Three health-care deals today are paying huge premiums

    UPDATE: Three health-care deals today are paying huge premiums

  4. UPDATE: Three health-care deals today are paying huge premiums

    UPDATE: Three health-care deals today are paying huge premiums

  5. Fitch Downgrades Allergan's Ratings; Affirms Actavis at 'BBB-'; Outlook Stable

    Fitch Downgrades Allergan's Ratings; Affirms Actavis at 'BBB-'; Outlook Stable

  6. Research and Markets: Allergan's Abicipar Pegol (Macular Edema and Macular Degeneration) Forecast and Market Analysis to 2023

    Research and Markets: Allergan's Abicipar Pegol (Macular Edema and Macular Degeneration) Forecast and Market Analysis to 2023

  7. Health Care: 3 Picks in a More Expensive Sector

    Despite the sector looking slightly overvalued overall, we still see stocks that offer attractive valuations across the different industries.

  8. UPDATE: Patent cliff continues to drive mergers in drug industry

    UPDATE: Patent cliff continues to drive mergers in drug industry

  9. Patent cliff continues to drive mergers in drug industry

    Patent cliff continues to drive mergers in drug industry

  10. Actavis Announces Pricing of Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan

    Actavis Announces Pricing of Public Offering of Senior Notes in Connection with Pending Acquisition of Allergan

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.